No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NAMS240816C15000
- 6.50
- 0.000.00%
15min DelayTrading Jul 5 13:55 ET
0.00High0.00Low
0.00Open6.50Pre Close0 Volume10 Open Interest15.00Strike Price0.00Turnover168.97%IV14.00%PremiumAug 16, 2024Expiry Date3.86Intrinsic Value100Multiplier25DDays to Expiry2.64Extrinsic Value100Contract SizeAmericanOptions Type0.7676Delta0.0364Gamma3.59Leverage Ratio-0.0518Theta0.0064Rho2.76Eff Leverage0.0152Vega
Intraday
- 5D
- Daily
News
NewAmsterdam Pharma Board Reshuffles, Welcomes Industry Experts
Express News | NewAmsterdam Pharma Announces Appointments of Mark C. Mckenna and Wouter Joustra to Its Board of Directors
Express News | NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 Tandem Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib Plus Ezetimibe in Patients With Hefh and/or Ascvd or Ascvd Risk Factors
NewAmsterdam Pharma Files $400M Mixed Securities Shelf
Express News | NewAmsterdam Pharma Company NV Files for Mixed Shelf of up to $400 Mln - SEC Filing
Leerink Partners Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $37
Leerink Partners analyst Roanna Ruiz maintains $NewAmsterdam Pharma(NAMS.US)$ with a buy rating, and maintains the target price at $37.According to TipRanks data, the analyst has a success rate of 32.
Comments
» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US$
$Vaxcyte(PCVX.US$
$Legend Biotech(LEGN.US$
$Janux Therapeutics(JANX.US$
$Aerovate(AVTE.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Evolent Health(EVH.US$
$NewAmsterdam Pharma(NAMS.US$
$RxSight(RXST.US$
$TYRA BIOSCIENCES, INC.(TYRA.US$
$Edgewise Therapeutics(EWTX.US$
$4D Molecular Therapeutics(FDMT.US$
$Biogen(BIIB.US$
$PepGen(PEPG.US$
...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US$
$Vaxcyte(PCVX.US$
$Legend Biotech(LEGN.US$
$Janux Therapeutics(JANX.US$
$Aerovate(AVTE.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Evolent Health(EVH.US$
$NewAmsterdam Pharma(NAMS.US$
$RxSight(RXST.US$
$TYRA BIOSCIENCES, INC.(TYRA.US$
$Edgewise Therapeutics(EWTX.US$
$4D Molecular Therapeutics(FDMT.US$
$Biogen(BIIB.US$
$PepGen(PEPG.US$
...
7
Analysts have upgraded revenue forecasts for NewAmsterdam Pharma next year, despite slower expected growth than the industry. They also increased the price target, indicating an improved intrinsic business value.
1
$NewAmsterdam Pharma(NAMS.US$ sold with few percentages uptrend indicator left sky 👍🏻
$NewAmsterdam Pharma(NAMS.US$ awsome 10% up top gainer in portfolio more potential here
Read more